Literature DB >> 32920883

Metabolomic differences of exhaled breath condensate among children with and without asthma.

Ju Chang-Chien1, Hsin-Yi Huang1, Hui-Ju Tsai2, Chi-Jen Lo3, Wan-Chen Lin1, Yu-Lun Tseng1, Shih-Ling Wang1, Hung-Yao Ho3,4,5, Mei-Ling Cheng3,4,6, Tsung-Chieh Yao1,7.   

Abstract

BACKGROUND: There remains an unmet need in objective tests for diagnosing asthma in children. The objective of this study was to investigate the potential of metabolomic profiles of exhaled breath condensate (EBC) to discriminate stable asthma in Asian children in the community.
METHODS: One hundred and sixty-five Asian children (92 stable asthma and 73 non-asthmatic controls) participating in a population-based cohort were enrolled and divided into training and validation sets. Nuclear magnetic resonance-based metabolomic profiles of EBC samples were analyzed by using orthogonal partial least squares discriminant analysis.
RESULTS: EBC metabolomic signature (lactate, formate, butyrate, and isobutyrate) had an area under the receiver operator characteristic curve (AUC) of 0.826 in discriminating children with and without asthma in the training set, which significantly outperformed FeNO (AUC = 0.574; P < .001) and FEV1 /FVC % predicted (AUC = 0.569; P < .001). The AUC for EBC metabolomic signature was 0.745 in the validation set, which was slightly but not significantly lower than in the testing set (P = .282). We further extrapolated two potentially involved metabolic pathways, including pyruvate (P = 1.67 × 10-3 ; impact: 0.14) and methane (P = 1.89 × 10-3 ; impact: 0.15), as the most likely divergent metabolisms between children with and without asthma.
CONCLUSION: This study provided evidence supporting the role of EBC metabolomic signature to discriminate stable asthma in Asian children in the community, with a discriminative property outperforming conventional clinical tests such as FeNO or spirometry.
© 2020 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Entities:  

Keywords:  asthma; butyrate; diagnosis; exhaled breath condensate; formate; isobutyrate; lactate; metabolomics

Year:  2020        PMID: 32920883     DOI: 10.1111/pai.13368

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  6 in total

Review 1.  Asthma and the Missing Heritability Problem: Necessity for Multiomics Approaches in Determining Accurate Risk Profiles.

Authors:  Tracy Augustine; Mohammad Ameen Al-Aghbar; Moza Al-Kowari; Meritxell Espino-Guarch; Nicholas van Panhuys
Journal:  Front Immunol       Date:  2022-05-25       Impact factor: 8.786

2.  Comments on metabolomics in asthma and atopic dermatitis, and patient care during the COVID-19 pandemic.

Authors:  Philippe Eigenmann
Journal:  Pediatr Allergy Immunol       Date:  2021-11       Impact factor: 6.377

3.  Early-life weight gain is associated with non-atopic asthma in childhood.

Authors:  Chia-Hua Ho; Chun-Chun Gau; Wan-Fang Lee; Hsin Fang; Ching-Hua Lin; Chun-Hui Chu; Yin-Shan Huang; Yu-Wen Huang; Hsin-Yi Huang; Hui-Ju Tsai; Tsung-Chieh Yao
Journal:  World Allergy Organ J       Date:  2022-07-31       Impact factor: 5.516

4.  Temporal Dynamics of the Nasopharyngeal Microbiome and its Relationship with Childhood Asthma Exacerbation.

Authors:  Jinpao Hou; Yuping Song; Agnes Sze Yin Leung; Man Fung Tang; Mai Shi; Evy Yiwei Wang; Joseph Gar Shun Tsun; Renee Wan Yi Chan; Gary Wing Kin Wong; Stephen Kwok-Wing Tsui; Ting Fan Leung
Journal:  Microbiol Spectr       Date:  2022-05-12

5.  Association of advanced paternal age with lung function at school age.

Authors:  Chun-Chun Gau; Hsin-Ju Lee; Hung-Yi Lu; Chao-Yi Wu; Hsin-Yi Huang; Hui-Ju Tsai; Tsung-Chieh Yao
Journal:  Respir Res       Date:  2022-09-20

6.  Cord blood IgE predicts allergic sensitization, elevation of exhaled nitric oxide, and asthma in schoolchildren.

Authors:  Hsin-Ju Lee; Hui-Ju Tsai; Hsin-Yi Huang; Chun-Chun Gau; Chia-Hua Ho; Jing-Long Huang; Tsung-Chieh Yao
Journal:  Pediatr Allergy Immunol       Date:  2022-08       Impact factor: 5.464

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.